Milran 12.5 mg (Tablet)
Unit Price: ৳ 6.02 (5 x 10: ৳ 301.00)
Strip Price: ৳ 60.20
Medicine Details
| Category | Details |
|---|---|
| Generic | Milnacipran hydrochloride |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Management of fibromyalgia
Pharmacology
- Potent inhibitor of neuronal norepinephrine and serotonin reuptake
Dosage
- Recommended dose of 100 mg/day
- May be titrated based on efficacy and tolerability
Administration
- Should be taken with food
- Preferably taken during meals
Interaction
- Increased risk of bleeding with certain drugs
- Increased CNS effects with centrally-acting drugs
- Increased risk of serotonin syndrome and NMS-like reactions with certain drugs
- May inhibit antihypertensive effect of clonidine
- May potentiate adverse haemodynamic effects with digoxin
- Possible occurrence of paroxysmal HTN and cardiac arrhythmia with epinephrine or norepinephrine
Contraindications
- Uncontrolled narrow-angle glaucoma
- Concomitant use with MAOI or within 2 wk after withdrawal of MAOI
Side Effects
- Increased heart rate
- HTN
- Increased liver enzymes
- Severe liver injury
- Hyponatraemia
- Abnormal bleeding
- Dysuria
- Nausea
- Vomiting
- Constipation
- Headache
- Insomnia
- Dizziness
- Hot flushes
- Hyperhidrosis
- Palpitations
- Dry mouth
- Migraine
Pregnancy & Lactation
- Patients should notify physician if pregnant or intend to become pregnant
- Encouraged to enroll in the Milnacipran Pregnancy Registry
- Advise patients to notify physician if breastfeeding
Precautions & Warnings
- Applicable to patients with major depressive disorder or psychiatric disorders
- History of dysuria
- Controlled narrow-angle glaucoma
- Pre-existing HTN
- Tachyarrhythmias or other CV disease
- History of seizure disorder or condition predisposing to seizures
- Avoid abrupt withdrawal
- Severe hepatic and moderate to severe renal impairment including ESRD
- Pregnancy and lactation
Use in Special Populations
- Dosage adjustment for severe renal impairment
- Not recommended in end-stage renal disease
- Not recommended in pediatric patients
Overdose Effects
- Symptoms include increased BP, cardio-resp arrest, changes in the level of consciousness, confusional state, dizziness, and increased hepatic enzymes
- Management with symptomatic treatment, gastric lavage, activated charcoal, maintaining adequate airway, oxygenation, and ventilation, monitoring cardiac rhythm and vital signs, possible use of cyproheptadine for serotonin syndrome
Therapeutic Class
- Serotonin-norepinephrine reuptake inhibitor (SNRI)
Storage Conditions
- Store at 25° C